Dublin, Feb. 07, 2019 (GLOBE NEWSWIRE) -- The "Sepsis Therapeutics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2024. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million. The report profiles 24 companies including many key and niche players such as:

  • Adrenomed AG (Germany)
  • AM-Pharma B.V. (Netherlands)
  • AMOMED Pharma GmbH (Austria)
  • Asahi Kasei Pharma America (USA)
  • Endacea, Inc. (USA)
  • InflaRx N.V. (Germany)
  • La Jolla Pharmaceutical Company (USA)
  • TaiRx, Inc. (USA)

Key Topics Covered:

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study 2. INDUSTRY OVERVIEW Sepsis - A Prelude New Treatment Protocols and New Definitions - Every Minute Counts!! Aging Population: A Key Growth Driver for Sepsis Therapeutics Antibiotics and Vasopressors - The Current Standard of Care Current Categories of Antibacterial Agents for First-line Sepsis Treatment Current Anti-bacterial Drugs used in Sepsis Current Antifungals used for Sepsis Current Antivirals used for Sepsis GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment Argipressin Gains Approval for Septic Shock in 26 EU countries Current & Future Analysis Growth Drivers in a Nutshell Market Restraints 3. MARKET DYNAMICS A Market Characterized by High Unmet Medical Needs Research Activity Enables Increased Awareness of Disease Pathogenesis Select Sepsis Therapeutics under Phase IV Clinical Trials: As of 2018 Select Sepsis Therapeutics under Phase III Clinical Trials: 2018 Novel Immune-Specific Modes of Action under Focus Emphasizing on Endothelial Cell Function HMGB1- A Potential Target for Future Therapies Nanoparticle Systems Demonstrate Potential for Use in Septic Shock Management Researchers Employ IL-7 to Increase CD4 and CD8 Immune Cells in Patients Hydrocortisone Displays Potential in Septic Shock Treatment Reduced Levels of Vitamin C Characterize Sepsis Patients Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market Researchers Develop ss-Sepsis-3 Protocol for Evaluation of Sepsis in Animal Models World Sepsis Day Aims to Result in Improvement in Sepsis Management NSAIDs Demonstrate Potential to Treat Sepsis 4. SEPSIS: AN OVERVIEW Sepsis - A Major Life-Threatening Condition Risk Profile Most Vulnerable Groups: Newborns and the Elderly A Growing Threat in Hospital Environment Types of Sepsis SIRS Uncomplicated Sepsis Severe Sepsis Septic Shock Septicemia Bacteremia Mortality Rates Mortality Rate on a Decline Hospital Re-Admission Rate Remains High Symptoms to Identify Sepsis Patients General Symptoms in Sepsis Patients Symptoms Specific to Source of Infection Biological Changes in Sepsis Patients Organ Dysfunction Symptoms in Acute Cases Common Sources of Sepsis Stages of Sepsis' Progression Treatment of Sepsis General Approaches for Treatment of Severe Sepsis and Septic Shock Overview of Traditional Treatment Approaches Anti-microbials Drug Resistance: The Major Threat to Sepsis Standby Antibiotics Vasopressors Corticosteroids Immunoglobulins Anticoagulants Neonatal Sepsis 5. COMPETITIVE LANDSCAPE 5.1 Focus on Select Global Players 5.2 Product Introductions/Approvals Asahi Kasei Pharma Obtains Phase III Clinical Study Results for ART-123 Argipressin Receives Approval in 26 EU Countries La Jolla Pharmaceutical Receives FDA Approval for Giapreza Injection Sepsis Alliance Partners with La Jolla Pharmaceutical 6. GLOBAL MARKET PERSPECTIVE 7. REGIONAL MARKET PERSPECTIVE 7.1 The United States A. Market Analysis United States: The Largest Market for Sepsis Therapeutics Alarming Incidence of Sepsis & Lack of Therapies Aging Population: A Key Growth Factor 7.2 Rest of World A. Market Analysis Aging Population: Key Opportunity Indicator India India: High Incidence of Neonatal Sepsis Key Opportunity Indicator: Aging Population Statistics in Rest of World 8. COMPANY PROFILES

Total Companies Profiled: 24 The United States (7)

  • Canada (3)
  • Japan (1)
  • Europe (8)
    • France (1)
    • Germany (4)
    • Rest of Europe (3)
  • Asia-Pacific (Excluding Japan) (4)
  • Middle East (1)

For more information about this report visit https://www.researchandmarkets.com/research/m...epsis?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Infectious Diseases Drugs